Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.46 |
| ▸ | KIF5B | P33176 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | ADK | P55263 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 8/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443270 | 0.87 | ADK (0.43) | RETKIF5BKDRADKABL1 | |
| SCHEMBL16769693 | 0.80 | METTL3 (0.50) | RETKIF5BKDRADKABL1 | |
| SCHEMBL18925745 | 0.80 | METTL3 (0.50) | RETKIF5BKDRADKABL1 | |
| SCHEMBL1444002 | 0.80 | RET (0.69) | RETKIF5BKDRADKABL1 | |
| SCHEMBL1444001 | 0.80 | RET (0.69) | RETKIF5BKDRADKABL1 | |
| SCHEMBL6108827 | 0.79 | HCK (0.45) | RETKDRADKABL1NTRK1 | |
| SCHEMBL6108831 | 0.79 | HCK (0.45) | RETKDRADKABL1NTRK1 | |
| SCHEMBL27880596 | 0.78 | RET (0.44) | RETKIF5BKDRADKABL1 | |
| SCHEMBL27864236 | 0.78 | RET (0.52) | RETKIF5BKDRADKABL1 | |
| SCHEMBL16769992 | 0.76 | ABL1 (0.63) | KDRADKABL1LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | RET 853/4885KIF5B 2516/4885KDR 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.